South Korea
· Delayed Price · Currency is KRW J2KBIO Statistics
Total Valuation
J2KBIO has a market cap or net worth of KRW 102.16 billion. The enterprise value is 92.33 billion.
| Market Cap | 102.16B |
| Enterprise Value | 92.33B |
Important Dates
The next estimated earnings date is Friday, November 22, 2024.
| Earnings Date | Nov 22, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
J2KBIO has 5.71 million shares outstanding. The number of shares has decreased by -0.41% in one year.
| Shares Outstanding | 5.71M |
| Shares Change (YoY) | -0.41% |
| Shares Change (QoQ) | +12.46% |
| Owned by Insiders (%) | 63.48% |
| Owned by Institutions (%) | 6.91% |
| Float | 2.09M |
Valuation Ratios
The trailing PE ratio is 92.19.
| PE Ratio | 92.19 |
| Forward PE | n/a |
| PS Ratio | 2.59 |
| PB Ratio | 3.33 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 11.96, with an EV/FCF ratio of -931.63.
| EV / Earnings | 91.47 |
| EV / Sales | 2.57 |
| EV / EBITDA | 11.96 |
| EV / EBIT | 13.36 |
| EV / FCF | -931.63 |
Financial Position
The company has a current ratio of 6.45, with a Debt / Equity ratio of 0.12.
| Current Ratio | 6.45 |
| Quick Ratio | 5.54 |
| Debt / Equity | 0.12 |
| Debt / EBITDA | 0.45 |
| Debt / FCF | -34.74 |
| Interest Coverage | 53.73 |
Financial Efficiency
Return on equity (ROE) is 4.42% and return on invested capital (ROIC) is 17.31%.
| Return on Equity (ROE) | 4.42% |
| Return on Assets (ROA) | 15.27% |
| Return on Capital (ROIC) | 17.31% |
| Revenue Per Employee | 690.80M |
| Profits Per Employee | 19.41M |
| Employee Count | 52 |
| Asset Turnover | 1.27 |
| Inventory Turnover | 8.59 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 19,139.80 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 44.45 |
| Average Volume (20 Days) | 35,642 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, J2KBIO had revenue of KRW 35.92 billion and earned 1.01 billion in profits. Earnings per share was 193.94.
| Revenue | 35.92B |
| Gross Profit | 14.38B |
| Operating Income | 6.91B |
| Pretax Income | 1.82B |
| Net Income | 1.01B |
| EBITDA | 7.72B |
| EBIT | 6.91B |
| Earnings Per Share (EPS) | 193.94 |
Balance Sheet
The company has 13.28 billion in cash and 3.44 billion in debt, giving a net cash position of 9.83 billion or 1,720.98 per share.
| Cash & Cash Equivalents | 13.28B |
| Total Debt | 3.44B |
| Net Cash | 9.83B |
| Net Cash Per Share | 1,720.98 |
| Equity (Book Value) | 29.83B |
| Book Value Per Share | 5,370.33 |
| Working Capital | 20.43B |
Cash Flow
In the last 12 months, operating cash flow was 4.16 billion and capital expenditures -4.26 billion, giving a free cash flow of -99.11 million.
| Operating Cash Flow | 4.16B |
| Capital Expenditures | -4.26B |
| Free Cash Flow | -99.11M |
| FCF Per Share | -17.34 |
Margins
Gross margin is 40.04%, with operating and profit margins of 19.25% and 2.81%.
| Gross Margin | 40.04% |
| Operating Margin | 19.25% |
| Pretax Margin | 5.07% |
| Profit Margin | 2.81% |
| EBITDA Margin | 21.50% |
| EBIT Margin | 19.25% |
| FCF Margin | -0.28% |
Dividends & Yields
J2KBIO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.41% |
| Shareholder Yield | 0.41% |
| Earnings Yield | 1.08% |
| FCF Yield | -0.10% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
J2KBIO has an Altman Z-Score of 13.51.
| Altman Z-Score | 13.51 |
| Piotroski F-Score | n/a |